105 completed. 105 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 105 | Completed 105 |
| Phase 2 | 1 | Completed 1 |
Follow Pneumococcal Infections: new trials by email Literature Review of Pneumococcal Infections trials Research Report on Pneumococcal Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 31 valent pneumococcal conjugate vaccine, PCV20, PCV21 - Pneumococcal Disease | Phase 3 | Completed | Vaxcyte, Inc. | 4049 | 2025-12-01 | 2026-10-16 |
| A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013) V116, PPSV23 - Pneumococcal Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 882 | 2024-01-18 | 2026-03-11 |
| A Study to Learn About the Safety and Immune Response of 20vPnC in Adults in India. 20-valent pneumococcal conjugate vaccine - Pneumococcal Disease | Phase 3 | Completed | Pfizer | 405 | 2023-08-16 | 2024-10-24 |
| Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008) V116, Placebo, PCV15 - Pneumococcal Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 518 | 2023-02-13 | 2026-03-03 |
| Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9) V116, PPSV23 - Pneumococcal Disease | Phase 3 | Completed | Merck Sharp & Dohme LLC | 450 | 2023-01-10 | 2024-10-02 |
| Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10) V116, PPSV23 - Pneumococcal Disease | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1484 | 2022-11-07 | 2026-03-02 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5) V116, QIV, Matching Placebo for V116 - Pneumonia, Pneumococcal | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1080 | 2022-09-23 | 2025-10-29 |
| A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine - Pneumococcal Disease | Phase 3 | Completed | Pfizer | 541 | 2022-09-16 | 2025-12-15 |
| A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4) V116, PPSV23 - Pneumococcal Disease | Phase 3 | Completed | Merck Sharp & Dohme LLC | 2162 | 2022-08-12 | 2024-09-24 |
| Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7) V116, Placebo, PCV15 - Pneumococcal Disease | Phase 3 | Completed | Merck Sharp & Dohme LLC | 313 | 2022-07-13 | 2026-02-05 |
| Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3) V116, PCV20 - Pneumococcal Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 2663 | 2022-07-13 | 2024-10-26 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6) V116, PCV15, PPSV23 - Pneumonia, Pneumococcal | Phase 3 | Completed | Merck Sharp & Dohme LLC | 717 | 2022-07-12 | 2024-10-26 |
| Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine - Pneumococcal Disease | Phase 3 | Completed | Pfizer | 356 | 2022-06-24 | 2024-09-19 |
| Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911) V110, V114, mRNA-1273 - Pneumococcal Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 850 | 2022-01-12 | 2025-07-18 |
| Clinical Study on the Combined Administration of 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus, Pertussis Vaccine 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed), Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed) - Streptococcus Pneumoniae Infections | Phase 3 | Completed | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 1110 | 2021-09-16 | 2025-02-10 |
| 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan 20vPnC, Saline, 13vPnC - Pneumococcal Disease | Phase 3 | Completed | Pfizer | 1425 | 2021-06-14 | 2024-11-05 |
| Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2 20-valent pneumococcal conjugate vaccine (20vPnC), BNT162b2, Saline - Pneumococcal Disease, COVID-19 | Phase 3 | Completed | Pfizer | 570 | 2021-05-20 | 2022-12-14 |
| Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i) 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine - Pneumococcal Infections, Streptococcal Infections | Phase 3 | Completed | CanSino Biologics Inc. | 3420 | 2021-04-13 | 2024-04-02 |
| Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036) V114 - Pneumococcal Disease | Phase 3 | Completed | Merck Sharp & Dohme LLC | 58 | 2021-02-10 | 2024-09-24 |
| Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age 20vPnC - Pneumococcal Disease | Phase 3 | Completed | Pfizer | 839 | 2020-12-04 | 2024-01-22 |
Showing 20 of 105. Sign in to see all of them.
Streptococcal Infections (22) · Pneumonia, Pneumococcal (7) · Acquired Immunodeficiency Syndrome (3) · Diphtheria (3) · HIV Infections (3) · Otitis Media (3) · Tetanus (3) · Fever (2) · Meningococcal Infections (2) · Pneumonia (2) · Poliomyelitis (2) · Rotavirus Infections (2) · Anemia, Sickle Cell (1) · Bacterial Infections (1)
Bacterial Infections and Mycoses (105) · Infections (105) · Bacterial Infections (104) · Gram-Positive Bacterial Infections (104) · Streptococcal Infections (83) · Respiratory Tract Diseases (13) · Respiratory Tract Infections (12) · Virus Diseases (11) · Lung Diseases (10) · RNA Virus Infections (10) · Pneumonia (8) · Pneumonia, Bacterial (7) · Blood-Borne Infections (5) · Communicable Diseases (5)
13-valent pneumococcal vaccine (21) · 23-valent pneumococcal capsular polysaccharide vaccine (14) · PHiD-CV vaccine (10) · diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (10) · Heptavalent Pneumococcal Conjugate Vaccine (9) · Pneumococcal Vaccines (7) · RIX4414 vaccine (6) · 2,4,5,4'-tetrachlorodiphenylsulfoxide (5) · Hiberix (5) · Sodium Chloride (5) · Chickenpox Vaccine (3) · Pentetic Acid (3) · Tritanrix-HepB vaccine (3) · Acetaminophen (2) · Blood Specimen Collection (2)
Merck Sharp & Dohme LLC (33) · Pfizer (26) · GlaxoSmithKline (25) · SK Chemicals Co., Ltd. (3) · Wyeth is now a wholly owned subsidiary of Pfizer (3) · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (2) · PATH (2) · CanSino Biologics Inc. (1) · Finnish Institute for Health and Welfare (1) · Menzies School of Health Research (1) · Sanofi Pasteur, a Sanofi Company (1) · Sinovac Biotech Co., Ltd (1) · UMC Utrecht (1) · University Hospital, Tours (1) · University of British Columbia (1)
United States (34) · Poland (14) · Spain (12) · Australia (10) · Canada (10) · Finland (10) · Japan (10) · South Korea (10) · Sweden (10) · Taiwan (10) · France (8) · Germany (8) · Thailand (8) · Chile (7) · Belgium (6)
Amanda J Leach, PhD (1) · Andrew J Pollard, BSc MBBS PhD MRCP FRCPCH (1) · Du Lin, Master (1) · Ed Clarke (1) · Ed Clarke, MB ChB, PhD (1) · Edward K Mulholland, DM (1) · Elisabeth A. M. Sanders, MD, PhD (1) · Francesca Montagnani, MD, PhD (1) · Jonathan R Carapetis, PhD (1)
PMID 25008901, PMID 36368038, PMID 37846456, PMID 41187484, PMID 11172176, PMID 14557958, PMID 19325447, PMID 19325451, PMID 19325452, PMID 19584345, PMID 20088694, PMID 20823436, PMID 20980796, PMID 21695210, PMID 21807056, PMID 21813135, PMID 21860256, PMID 23658394, PMID 23804191, PMID 24120678, PMID 24356787, PMID 24447437, PMID 24921688, PMID 25278086, PMID 25329446, PMID 25355940, PMID 25395187, PMID 25499011, PMID 25888646, PMID 26020101, PMID 26506438, PMID 26529076, PMID 27149114, PMID 27254028, PMID 27258647, PMID 27422342, PMID 28079828, PMID 28087146, PMID 28425818, PMID 28987445, PMID 30215583, PMID 30603376, PMID 31364010, PMID 31626050, PMID 31995183, PMID 32035706, PMID 32966176, PMID 33245004, PMID 33516293, PMID 34019468
2018 (13), 2019 (7), 2017 (3), 2014 (2), 2009 (1), 2015 (1), 2023 (1)